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Abstract
Background: Acute encephalitis syndrome (AES) is a public health problem in India. Neuroinfections are believed
to be the most important etiology. Minocycline is a semisythetic tetracycline having excellent penetration into
cerebrospinal fluid, established neuroprotective and antiviral properties besides action on nonviral causes of AES. It
has been shown to be effective in animal model of Japanese encephalitis (JE). A randomized, controlled trial of
nasogastric/oral minocycline in JE and AES at a single centre in Uttar Pradesh, northern India, was therefore conducted.
Methods: Patients beyond 3 years of age - but excluding women aged 16–44 years - hospitalized with AES
of < =7 days duration were enrolled and block randomized to receive nasogastric/oral minocycline or placebo
suspension and followed up. Patients, study personnel and those entering data were blinded as to drug or
placebo received. Primary outcome was cumulative mortality at 3 months from hospitalization. Analysis was
by intention to treat.
Results: 281 patients were enrolled, 140 received drug and 141 placebo. While there was no overall
statistically significant difference in 3 month mortality between drug and placebo groups [RR = 0 · 83 (0 · 6-1 ·
1)], there were encouraging trends in patients older than 12 years [RR = 0.70 (0.41-1.18)] and in Glasgow
Outcome Score (GOS) at 3 months (χ2 = 7 · 44, p = 0 · 059). These trends were further accentuated if patients
dying within one day of reaching hospital were excluded [OR for 3 month mortality =0 · 70 (0 · 46-1 · 07),
p = 0.090; 3 month GOS p = 0 · 028].
Conclusions: A trend towards better outcomes was observed with minocycline, especially in those patients
who survived the initial day in hospital. These findings should form the basis for planning a larger study and
possibly including minocycline in the initial management of AES as seen here.
Trial registration: The trial was registered with Clinical Trials Registry of India (CTRI) - CTRI/2010/091/006143
Keywords: randomized controlled trial, minocycline, acute encephalitis syndrome
Background
Acute onset of fever with alteration in consciousness is
an important cause of hospital admissions in large parts
of India. Such a presentation is most commonly caused
by invasion of the brain by an infectious agent – virus,
bacteria, protozoa, rickettsiae, mycoplasma etc. Other
causes include noninfectious brain inflammations,
infectious encephalopathies and other functional and
structural brain disorders if associated with fever due to
another cause. In 2006, the World Health Organization
(WHO) coined the term ‘acute encephalitis syndrome’
(AES) for surveillance purposes [1]. AES is a symptom
complex the etiology of which may change with region
and time. In many parts of India, Japanese encephalitis
(JE) is the most important cause of such an illness.
Uttar Pradesh is India’s most populous and one of its
poorest states, with low human development indices [2].
The state is endemic for JE since the 1970s and there
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are annual outbreaks of this illness in the monsoon/
postmonsoon season in its eastern districts. In 2005 a
severe epidemic of JE occurred here [3], after which the
Government of India started a vaccination drive using
the Chinese live attenuated vaccine (SA-14-14-2 strain)
[4]. Even so our hospital continues to receive 1000–1200
patients of AES annually, some of which are proven to
be JE. An etiological diagnosis is not reached in most pa-
tients. Treatment is mainly supportive, intravenous cef-
triaxone is usually used and empirical acyclovir used
occasionally.
The drug Minocycline is a semisynthetic tetracycline.
Its use has been especially directed towards the central
nervous system because of its lipophilic nature and abil-
ity to cross the blood brain barrier. Antibiotic action is
through interference with 30-S ribosome. Yrjanheikki
et al. (1998) demonstrated that it was neuroprotective in
animal model of ischemia [5]. Its neuroprotective prop-
erties have since been demonstrated in diverse central
nervous system (CNS) injuries including some viral en-
cephalitides. Protective effect has been seen against hyp-
oxic injury [6], ischemic stroke [7], amyotrophic lateral
sclerosis [8], traumatic spinal cord injury [9–11], mul-
tiple sclerosis [12], Parkinson’s disease [13], Huntington’s
disease [14] and diabetic retinopathy [15]. In a murine
model of reovirus encephalitis, minocycline delayed dis-
ease onset and progression. Virus-induced CNS injury,
apoptosis, virus titre and antigen expression were signifi-
cantly decreased in the brains of minocycline-treated
mice [16, 17]. In an in vivo simian immunodeficiency
virus model of HIV CNS disease, minocycline reduced
the severity of encephalitis, suppressed viral load in the
brain and decreased the expression of CNS inflamma-
tory markers [18]. In an in vitro model, effect of tetracy-
clines on replication of West Nile virus (WNV) was
studied by cytopathic effects and virus yield reduction
assay. Minocycline exerted the strongest anti-WNV ac-
tivity [19].
Mishra and Basu (2008) investigated the effect of min-
ocycline in an experimental mouse model of JE. Intra-
venous inoculation of GP78 strain of JEV in adult mice
resulted in lethal encephalitis. Minocycline conferred
complete protection in mice following JEV infection (p
< 0.0001). Neuronal apoptosis, microglial activation, ac-
tive caspase activity, proinflammary mediators and viral
titres were markedly decreased in minocycline treated
JEV infected mice on ninth day post infection. These au-
thors concluded that minocycline was a candidate to
consider in human clinical trials in JE [20–22]. The drug
is already available for human use and is relatively safe.
We therefore proposed a randomized, controlled trial to
study the efficacy of minocycline in JE and AES. The ra-
tionale for its use in AES was threefold: firstly its neuro-
protective properties, secondly its antiviral properties
and thirdly its action against nonviral agents like rickett-
siae and Mycoplasma which may well contribute to AES
in this region. To the best of our knowledge this is the
first trial of minocycline in AES.
Methods
A parallel randomized double blind placebo controlled
trial with allocation ratio of 1:1 was planned at a
single site.
Study site
The study was based in the pediatric and adult medicine
wards of King George’s Medical University (KGMU)
hospital in Lucknow - the capital city of Uttar Pradesh.
This is a teaching hospital which caters mostly to the
poor and seriously ill from the city and surrounding dis-
tricts extending upto Nepal.
Prior approval for the trial was obtained from the In-
stitutional Ethics Committee and Drug Controller Gen-
eral of India (DCGI). Consent and adverse event forms
were filled up for each patient. A Data Safety Monitoring
Board (DSMB) with nine members was formed.
Drug and placebo
Minocycline hydrochloride and placebo powder for sus-
pension were obtained from Unimark Remedies, India in
identical bottles. Placebo differed from drug in the active
ingredient being absent. The bottles were supplied in
lots – four bottles/lot for children upto 12 years old and
three bottles/lot for older patients. All the bottle lots
were labeled individually at INCLEN before sending to
the study site for use. The bottles bearing same lot ID
were used for only one patient.
Randomisation & masking
The bottles of minocycline drug and placebo powder
were supplied to a 3rd party- an independent member
from International Clinical Epidemiology Network
(INCLEN), New Delhi, who generated the randomization
list with blocks of four. Separate randomization was done
for children aged < =12 years and older patients.
Contents of bottles (appearance, colour, smell) were
similar. The randomization sequence and code of the
bottle lots were kept in safe custody by INCLEN. The
patient, personnel assessing outcomes and person enter-
ing data were blinded as to drug or placebo received.
Screening
From late August 2012 to May 2013, we actively screened
patients hospitalized in pediatric (age < =12 years) and
adult medicine wards with AES for enrollment in the
study. Inclusion criteria for enrollment were i) age > three
years but excluding women of child bearing age (between
16 and 44 years) ii) Presence of AES defined as fever with
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altered sensorium of < = seven days duration. Exclusion
criteria were i) a firm alternative etiological diagnosis ii)
consent for participation not obtained and iii) some
contraindication to drug administration. Written informed
consent for participation in the study was taken from the
patient’s guardian. As patients were admitted, those meet-
ing inclusion criteria without any exclusion criteria were
enrolled and randomized to receive the next numbered
bottle lot. No changes to eligibility criteria or outcome
measures were made after commencement of the trial.
Enrollment, treatment and work up
At admission, a detailed history, physical and neuro-
logical examination was recorded on predesigned data
collection forms. Intracranial tension could not be mea-
sured but presence of hypertension with bradycardia or
decerebrate posturing or Cheyne Stokes type of breath-
ing were taken as suggestive of raised intracranial ten-
sion. A standardized work up of patients of AES as used
here was adopted - including blood counts, smear and
rapid test for malaria, blood urea, blood culture, serum
electrolytes, creatinine and liver function tests. Neuroim-
aging was done whenever possible. Cerebrospinal fluid
(CSF) if obtained by lumbar puncture by the treating
team was examined for cell count, sugar, protein, gram
stain and bacterial culture. Supportive treatment with
antipyretics, anticonvulsants, nursing care, intravenous
fluids, cerebral dehydrants, oxygen , ventilation and va-
sopressors as needed was given to patients. Intravenous
ceftriaxone was also usually administered for 7–10 days.
Minocycline (or placebo) suspension was reconstituted
and given through nasogastric tube for seven days at a
loading dose of 5 mg/kg/day followed by 2 · 5 mg/kg 12
hourly in children upto 12 years old and 200 mg loading
dose followed by 100 mg 12 hourly in older patients.
The agent was started by the study personnel soon after
the patient was enrolled and randomized. Code on the
bottle was recorded. Every dose administered was en-
tered on the case sheet and signed. If a dose was vom-
ited out within half hour it was repeated. If an
alternative diagnosis was made after starting the agent, it
was continued but specific treatment was also given.
Even if the agent was withdrawn due to some contra-
indication later on, the patient was followed up for out-
come. Contraindications were abnormal liver enzymes
greater than five times normal or abnormal renal func-
tion with blood urea exceeding 35 mmol/l, diarrhea, rash
or severe gastric bleeding.
ELISA tests
CSF and serum specimen were stored at 4 C and trans-
ported in ice to the Virology Laboratory, KGMU. IgM
against JEV in CSF was tested by IgM Capture ELISA
(MAC ELISA) using the National Institute of Virology
(Pune) kit [23] and in serum, by the Panbio Combo kit
(Australia). If a specimen collected within one week of
illness onset was negative, the test was repeated in
serum after an interval of 7–10 days.
Follow up and outcome
Patients were followed up daily till they left the hospital.
Blood counts, liver and renal function tests were re-
peated after one week or earlier if indicated. Time taken
to become convulsion free, afebrile, to start oral feeds
and total hospital stay were recorded. Generally patients
were discharged once they could be fed orally and were
afebrile.
Outcome in hospital was classified as discharge or
death. In many cases, the family of the patient preferred
to take the patient home once the outcome appeared
hopeless. This was called “leave against medical advice”
or LAMA. Patients who just left the hospital without
informing hospital staff were called ‘absconders’. Fam-
ilies of discharged patients were given appointments to
revisit the hospital.
Three months after, the families were contacted on
mobile phone and health of their patient was inquired
into. The interviewer was unaware of the agent (drug/
placebo) received by the patient. Primary outcome in the
study was cumulative mortality at 3 months from
hospitalization. If the patient was alive, special question-
naires were administered telephonically. Questions in-
cluded ability to walk, talk, epilepsy, mental functions,
vision, hearing, focal deficits, rigidity, and abnormal
movements. Overall outcome at 3 months was classified
as normal/near normal, independent functioning,
dependent, vegetative, or death as per the Glasgow Out-
come Scale (GOS) [24]. If the patient revisited the hos-
pital, GOS was again assessed and full neurological
examination done. In some patients who could not be
contacted, home visits were made.
Power
AES mortality in our hospital is 30 % (unpublished data).
To detect lowering of mortality to 15 % with 95 % confi-
dence, with sample of 135 patients per arm, power of
the study came to roughly 80 % [25].
Adverse events
Standardized adverse event forms were filled up for each
patient. Serious adverse events were reported within
24 hours and agent was discontinued.
Data management and analysis
Double data entry followed by data matching was done.
Analysis was done by the 3rd party (INCLEN). Secondary
outcome factors were days to become convulsion free,
days to become afebrile, days to start feeding orally,
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duration of hospital stay in days and GOS at three
months. Means were compared by ANOVA/student ‘t’
test and proportions by χ [2] test using Epi-info 3 · 5 · 4
software. Relative risks for death was calculated. Interim
analysis was planned after each season and criteria to
decode was observation of significant difference in pri-
mary outcome between the two groups. Kaplan Meier
survival curves were generated. Analysis was by
intention to treat.
Quality assurance
Study personnel were given training in study procedures.
Standard Operating Procedures were followed. A clinical
research organization was hired.
Results
Over the study period of 8 ½ months from 29th Au-
gust 2012 to 15th May 2013, a total of 394 patients
with AES fulfilled our inclusion criteria. As has been
seen in the past [26, 27], patients of AES had a short
history of abrupt onset of fever, often with headache
and vomiting. Within a few hours to days, convul-
sions also occurred, after which the patient lapsed
into coma. At this point the families sought
hospitalization, but by the time they reached the hos-
pital many were hemodynamically unstable. Some of
our patients had rash, splenomegaly, bleeding mani-
festations, swelling of the body or deranged liver
functions (Table 1).
Table 1 Baseline comparison of drug and placebo groups
Variable Drug (n = 140) Placebo (n = 141)
N/ Mean % / SD N/ Mean % / SD
Mean Age1 15 · 4 15 · 7 16 · 1 17 · 6
Male sex2 102 72 · 8 108 76 · 6
Mean weight for age1 73 · 6 15 · 3 75 · 92 17 · 62
Mean duration of illness at presentation1 5 · 3 1 · 8 5 · 3 1 · 9
Headache2 66 47 · 1 62 43 · 9
Convulsion2 102 72 · 8 105 74 · 4
Mean GCS at admission1 8 · 6 2 · 6 8 · 2 2 · 5
Rash2 21 15.0 16 11.3
Swelling2 25 17.8 19 13.5
Bleeding2 5 3.5 13 9.2
Spleen palpable2 9 6.4 14 9.9
Meningeal signs2 63 45 · 0 58 41 · 1
Focal deficit2 11 7 · 8 17 12 · 0
↑ Tone2 65 46.4 67 47.5
↑ ICT2 13 9 · 3 20 14 · 2
Decerebration2 8 5 · 7 13 9.2
Mean Hb (gm/l) 1 105 20 106 24
Mean TLC1 (x 109/ l) 12.5 8.6 13.6 8.2
Mean polymorph %1 69 · 13 13 · 65 70 · 29 14 · 9
Mean platelets1(x 109/ l) 143 · 3 95 · 4 166 · 2 214 · 8
Mean CSF protein1 (g/l) 0 · 80 0 · 78 0 · 91 1 · 3
Mean CSF/ blood sugar ratio1 0 · 56 0. ·2 0 · 55 0 · 21
Mean CSF cells (per cu mm) 1 114 · 2 304 · 2 283 · 1 1118 · 7
Mean sAST1 (u/l) 116 · 6 149 · 5 132 · 8 244 · 2
Mean sALT1(u/l) 103 · 8 203 · 4 124 · 5 355 · 3
Mean s Protein (g/l) 1 74 68 77 79
Mean s Albumin (g/l) 1 34 07 32 07
Mean s Urea1 (mmol/l) 15 · 2 8 · 6 17 · 3 11 · 1
Mean s creatinine1 (μmol/l) 97 · 2 79 · 6 106 · 1 79 · 6
1 Comparison of means by 2 sample t test; 2 comparison of proportions by Chi square test; GCS: Glasgow Coma score; ICT: intracranial tension; Hb: hemoglobin;
TLC: total leucocyte count; CSF: Cerebrospinal fluid; AST: aspartate transaminase; ALT: alanine transaminase; none of the differences are significant at p < 0 · 05
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Of the 394 patients seen, 113 were excluded and 281
were enrolled. Reasons for exclusion were : other diag-
noses –84; consent not obtained –10; very short hospital
stay –9 and gastric bleeding −10. Lumbar puncture was
done in 244 patients. Other diagnoses reached were hep-
atic encephalopathy –48; uremic encephalopathy −5;
bacterial meningitis –6; tuberculous meningitis –5; head
injury –3; febrile convulsions −5; other seizure disorder-
12. Figure 1 shows the flow diagram of patients in the
two arms,
Only 29 patients tested positive for JE. This number
was too small for a separate analysis with power of 0.3
only. One hundred and forty patients received drug and
141 received placebo. There were no significant baseline
differences between the two groups (Table 1).
The trial was stalled in June 2013 after nine months
following new requirements issued by the Drug Control-
ler General of India who notified modified guidelines in
2013 (after the commencement of this trial), regard-
ing the conduct of drug trials in India. These import-
antly included guidelines regarding compensation of
those on the treatment arm as well as in the placebo
arm. Because we were not sure of the implications of
the modified regulations in a disease with high intrin-
sic mortality and long term morbidity as AES, the
trial was stopped.
A total of 19 patients had some contraindication in
the form of pre-existing deranged liver (10) or renal
functions (7) or both (2). The results of these investiga-
tions were received after the agent had been started. In
four patients there were untoward events after the
agent was started (adverse events) - severe gastric
bleed and diarrhea in two patients each. The agent
was withdrawn in all these. There was no significant
difference between drug and placebo groups in the
frequency of adverse events.
Fig. 1 Flow Diagram showing enrollment and follow up in the two arms of the study
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Of the total 281 patients, 57 died in hospital, 36 left
against medical advice (LAMA), 6 absconded and 182
were discharged. Of the 57 patients who died in hospital,
27 (47 · 4 %) died within one day, 32 (56 · 1 %) within
2 days and 42 (73 · 7 %) within three days. Of the 224 pa-
tients who left the hospital alive, 214 could be followed
up for ascertainment of mortality at three months – 179
by phone alone, 33 by hospital visit and two by home
visit. There was no significant difference between treat-
ment groups in type of follow up. Of the 188 discharged
or absconded patients , 171 were alive, nine were dead
at three months, and eight could not be followed up. Of
the 36 patients who left against medical advice, 29 were
dead at three months, five were alive, and two could not
be followed up. Cumulative mortality at three months
was 95/271 (35 · 1 %).
The cumulative three month mortality according to
drug or placebo received shows no significant difference
(Table 2). Separate analysis was done for children upto
12 years of age and older patients and if all those lost to
follow up were considered dead or alive but again there
are no significant differences (Table 2), though those
over 12 years fared better (RR 0 · 7, CI 0 · 4 – 1 · 2, p = 0 ·
173). Figure 2 shows the Kaplan Meier survival graphs.
When the Glasgow Outcome Score at three months
was compared between treatment groups, the differ-
ence approached significance with better outcome
with drug ( p = 0 · 059) (Table 3).
Post hoc exploratory analyses stratifying for number of
doses received and Glasgow Coma Score at admission
did not reveal significant differences. However when pa-
tients dying within one day of admission were excluded,
there was significantly better overall outcome at three
months in those receiving minocycline (p = 0 · 028) and
also a trend towards lower cumulative 3 month mortality
(p = 0.090) (Tables 4 and 5).
Discussion
We set out to study the effect of minocycline in JE and
also AES. However, required sample size did not accrue
for any meaningful analysis of JE and we present results
only for all AES.
Our study setting is one of the poorest and most
underdeveloped in India. This trial reflects the difficulty
Table 2 Comparison of 3 month mortality in drug and placebo groups




N % N %
Dead 43 30·7 52 36·9 0·83 (0·60-1·15) 0·270
Alive 92 65·7 84 59·5
untraced 5 3·6 5 3·6
Age > 12 years (n = 100) N = 50 N = 50
Dead 15 30·0 21 42·0 0·70 (0·41-1·18) 0·173
Alive 32 64·0 25 50·0
untraced 3 6·0 4 8·0
Age < =12 years
(n = 181) N = 90 N = 91
Dead 28 31·1 31 34·1 0·92 (0·61-1·40) 0·709
Alive 60 66·6 59 63·7
untraced 2 2·2 1 1·1
Considering that all those lost to follow up were dead at 3 months
Dead 48 34·3 57 40·4 0·85 (0·63-1·15) 0·345
Alive 92 65·7 84 59·6
Considering that all those lost to follow up were alive at 3 months
Dead 43 30·7 52 36·9 0·83 (0·60-1·16) 0 · 274
Alive 97 69·3 89 63·1
JE IgM positive patients (29)
Dead (7) 2 28.6 5 71.4 0.33 (0.03-2.72) 0.384
Alive (20) 11 55.0 9 45.0
untraced (2) 2 28.6 0 0
*Chi square test RR: relative risk 95 % CI: 95 % confidence intervals
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of conducting trials in limited resource settings such as
ours, where regulatory laws are still evolving. Etiologic
diagnosis of encephalitis is an arduous and costly under-
taking even in more affluent settings. Although AES has
a seasonal occurrence here, it may have a varied etiology
and our patients of AES were likely a mixed group. Im-
portant causes in this region include JE, bacterial menin-
gitis and dengue encephalopathy [28]. Bacterial causes
are difficult to exclude because patients often have re-
ceived prior treatment outside which can change the
CSF findings and render the culture sterile. There are
also case series of nonviral causes like rickettsioses [29]
and leptospirosis [30] from various parts of the country.
Mycoplasma encephalitis though difficult to diagnose
may also occur [31]. In fact, ascertainment of etiology in
every patient is an almost unachievable target. Therefore
our approach was to conduct a trial with minocycline in
AES regardless of etiology. The drug is a known neuro-
protective agent, a suppressor of deleterious neuroin-
flammation and may act as an antiviral (as proven in
animal models of viral encephalitis) besides its primary
indication as an antibiotic.
We excluded children below three years because tetra-
cyclines are contraindicated in young children. All regis-
tered trials of minocycline in conditions such as autism
and fragile X syndrome included children beyond three
years. Women of child bearing age were excluded be-
cause of risk of teratogenicity with unknown early preg-
nancy. Only patients with short duration of illness a
week or less were included because the clinical course is
usually already decided beyond that time.
We used nasogastric or oral minocycline as use of
intravenous minocycline would be logistically difficult.
Minocycline has to be diluted in 5 ml water and imme-
diately further diluted in 500–1000 ml fluid (dextrose/
normal saline/Ringers) before administration [32]. Giv-
ing such a large volume of fluid twice daily may not be
feasible in a critically ill child. Nasogastric/oral route is
likely to be effective as minocycline being extremely
lipophilic, is almost completely absorbed after oral ad-
ministration with very good CSF penetration [33]. Oral
doxycycline has been used for treating intracranial
Fig. 2 Kaplan Meier Survival curves in the two groups. Agent 1
(darker line) = Drug
Table 3 Comparison of secondary outcomes in drug and placebo groups
Outcome Drug (140) Placebo (141) P
N/Mean %/SD N/Mean %/SD
Discharged2 92 65 · 7 90 63 · 8 0 · 740
Absconded2 3 2 · 1 3 2 · 1 0 · 992
LAMA2 14 10 · 0 22 15 · 6 0 · 159
Death in hospital2 31 22 · 1 26 18 · 4 0 · 440
Mean days to become afebrile1 3 · 63 2 · 94 3.72 2 · 53 0 · 926
Mean days to become convulsion free1 1 · 35 1 · 14 1.22 0 · 87 0 · 411
Mean days to full consciousness1 3 · 37 2 · 6 3.06 2 · 19 0 · 399
Mean days to oral feeds1 3 · 06 2 · 71 3 · 21 2 · 85 0 · 702
Mean days till discharge1 6 · 86 4 · 97 6 · 66 4 · 39 0 · 721
Glasgow Outcome scale at 3 months2Normal/near
normal Independent Dependent Vegetative Dead
75314043 53 · 62 · 110 · 00.030 · 7 601111052 42 · 57 · 87 · 80.036 · 9 Chi Square = 7 · 44
P = 0 · 059
3 month GOS Unknown 5 3 · 5 7 4 · 9
1 Comparison of means by 2 sample t test; 2 comparison of proportions by Chi square test; SD: standard deviation,
LAMA: left against medical advice; GOS: Glasgow Outcome score
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infections like neurosyphilis and lyme neuroborreliosis
with results equivalent to intravenous ceftriaxone [34, 35].
Minocycline is twice as lipid soluble as doxycycline with
better CSF penetration [36]. We used a dose of drug
which is somewhat similar to that recommended in chil-
dren and adults [32] and for which safety and pharmaco-
kinetic data are available37. Delivery of drug through the
gastrointestinal route in a seriously sick child does not
guarantee absorption. On the other hand, CSF levels may
be higher in acute central nervous system infections due
to disruption of blood brain barrier. Since it was not pos-
sible to measure serum or CSF levels of minocycline, more
cannot be said about this. Our enrolled patients received a
variable number of minocycline doses, but randomization
would ensure that these differences were even between
the two groups.
AES as seen here often has a compact clinical course.
At first there is only fever with other nonspecific symp-
toms. The illness becomes clinically distinct after con-
vulsions or coma sets in. After this deterioration and
mortality may be swift. Travel to the city from far flung
rural areas would be initiated only after specific symp-
toms appear and could take time. Thus many patients
are already moribund when they reach our hospital. In
such case, even if the drug is started as soon as the pa-
tient arrives, there may be no benefit because the illness
has already wreaked havoc. Of the total in-hospital mor-
tality almost half (47 · 4 %) occurred within a day of ad-
mission. We could think of no way to counter this
difficulty when conducting such a trial.
In this study minocycline did not have statistically sig-
nificant benefit on cumulative mortality at three months
although an encouraging trend was seen in older age
group beyond 12 years. Effect on overall outcome at
3 months by GOS approached significance (p = 0 · 059).
However, a closer look at the data revealed that if we ex-
cluded patients who died very soon after reaching the
hospital, outcomes were significantly better in minocy-
cline treated group. Better overall three month outcome
was observed in patients who survived the initial day in
hospital. This indicates that the effect in the entire group
was being diluted because of inclusion of already mori-
bund and dying patients. Once these patients were ex-
cluded from the analysis, beneficial effect became
evident.
Conclusions
We conclude that there is a trend towards better out-
comes with minocycline in AES seen here, especially in
patients who survive the initial day in hospital. Exactly
how minocycline is effective - through its neuroprotec-
tive action, antiviral/antiapoptotic effect or direct effect
on nonviral agents or a combination of these, is unclear.
The care taken in designing and adhering to the laid out
protocol would ensure the reliability of the data. Our re-
sults would be applicable to Uttar Pradesh and large
parts of eastern and southern India and possibly other
regions of the world where AES has an unclear or some-
what similar etiology. Management of AES is a crucial
concern in this region and given its magnitude, even a
modest benefit assumes importance. These findings
could form the basis for planning a larger trial using the
same or different route of administration and dose of
minocycline in management of AES here.
Ethics approval
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